Effectiveness of Nicorandil with Trimetazidine with Coronary Heart Disease-Induced Chronic Heart Failure and Its Influence on Cardiac Function in Elderly

To determine the effectiveness of nicorandil in conjunction with trimetazidine on elderly individuals with coronary heart disease -induced chronic heart failure and its influence on the cardiac function. Between January 2018 and December 2022, a retrospective analysis was performed on the data of 248 elderly individuals with coronary heart disease -induced chronic heart failure treated in our hospital. All patients received routine basic treatment, with 110 patients treated with trimetazidine assigned to the control group, and the remaining 138 patients receiving both nicorandil and trimetazidine assigned to the study group. Prior to and after treatment, an evaluation of the cardiac function -related parameters (including left ventricular ejection fraction, left ventricular end -diastolic dimension, and N -terminal pro -brain natriuretic peptide) as well as inflammatory factors (C -reactive protein and interleukin-6) was performed and compared between the two groups. A comparison was made between the two groups regarding efficacy and adverse reactions, followed by logistic regression analysis to examine the risk factors affecting the patient's prognosis. Risk factors affecting the prognosis of patients, as identified by univariate analysis, included age, course of coronary heart disease, New York heart association classification, history of smoking, history of alcoholism, and medication regimen. The prognosis of individuals was found to be influenced by independent risk factors, namely New York heart association classification and medication regimen, as determined by multivariate logistic regression analysis. Effectively treating elderly individuals with coronary heart disease -induced chronic heart failure involves the utilization of nicorandil and trimetazidine in combination. This method not only promotes cardiac function recovery and enhances myocardial cells, but also mitigates inflammatory reactions, all while avoiding the occurrence of increased adverse reactions. Moreover, the prognosis of individuals was influenced by independent risk factors, namely New York heart association classification and medication regimen.